secwatch.observer — SEC 8-K summary
======================================

Issuer:     GYRE THERAPEUTICS, INC. (GYRE)
CIK:        0001124105
Form:       8-K
Filed at:   2024-08-08T23:59:59+00:00
Accession:  0001140361-24-036404
Event type: leadership
Sentiment:  neutral
Materiality: 0.50
Item codes: 5.02, 7.01, 8.01, 9.01
LLM model:  deepseek-v4-flash:cloud@v2

Gyre Therapeutics appoints David M. Epstein, Ph.D. to Board of Directors
------------------------------------------------------------------------

- David Epstein appointed as Class II director effective Aug 6, 2024; serves on Audit and Compensation Committees.
- Epstein co-founded Black Diamond Therapeutics (BDTX) and PairX Bio; former CSO of OSI Pharmaceuticals.
- Rodney Nussbaum appointed as Chair of Audit Committee on same date.

Source:
  EDGAR index:    https://www.sec.gov/Archives/edgar/data/1124105/000114036124036404/0001140361-24-036404-index.htm
  Primary doc:    https://www.sec.gov/Archives/edgar/data/1124105/000114036124036404/ef20033805_8k.htm
  HTML page:      https://secwatch.observer/filing/0001140361-24-036404

License: Source filings: public domain (SEC EDGAR). Summaries (headline + bullets): CC-BY-4.0; attribute https://secwatch.observer